GR852997B - - Google Patents

Info

Publication number
GR852997B
GR852997B GR852997A GR850102997A GR852997B GR 852997 B GR852997 B GR 852997B GR 852997 A GR852997 A GR 852997A GR 850102997 A GR850102997 A GR 850102997A GR 852997 B GR852997 B GR 852997B
Authority
GR
Greece
Prior art keywords
acid
pharmaceutical composition
active ingredients
novel pharmaceutical
cis vitamin
Prior art date
Application number
GR852997A
Other languages
Greek (el)
English (en)
Inventor
Paul J Jarosz
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of GR852997B publication Critical patent/GR852997B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GR852997A 1984-12-14 1985-12-12 GR852997B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68197084A 1984-12-14 1984-12-14

Publications (1)

Publication Number Publication Date
GR852997B true GR852997B (enExample) 1986-04-16

Family

ID=24737639

Family Applications (1)

Application Number Title Priority Date Filing Date
GR852997A GR852997B (enExample) 1984-12-14 1985-12-12

Country Status (9)

Country Link
EP (1) EP0184942B1 (enExample)
JP (1) JPS61145114A (enExample)
AT (1) ATE55247T1 (enExample)
AU (1) AU583568B2 (enExample)
CA (1) CA1282326C (enExample)
DE (1) DE3579128D1 (enExample)
DK (1) DK581185A (enExample)
GR (1) GR852997B (enExample)
PH (1) PH21591A (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5175002A (en) * 1991-10-02 1992-12-29 Du Pont Merck Pharmaceutical Company Amantadine hydrochloride syspension with enhanced dissolution characteristics for use in soft gelatin capsules
DE19603402A1 (de) * 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US6733779B2 (en) * 1999-08-26 2004-05-11 L. Dean Parks Method of treating benign prostatic hyperplasia and other benign prostate conditions
FR2807662A1 (fr) * 2000-04-12 2001-10-19 Cll Pharma Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications
IN192188B (enExample) * 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
WO2002024172A1 (en) 2000-09-22 2002-03-28 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
WO2003047497A1 (en) * 2001-12-06 2003-06-12 Ranbaxy Laboratories Limited Isotretinoin nanoparticulate compositions
EP1527774A1 (en) * 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010109259A1 (es) * 2009-03-26 2010-09-30 Grufarcol Ltda Métoda para preparar formulaciones de gel blando de isotretinoína líquida y la formulaciones obtenidas
CN102802729A (zh) 2009-05-20 2012-11-28 兰贝克赛实验室有限公司 异维a酸的液体剂型
BRPI1010972A2 (pt) 2009-05-20 2019-04-16 Ranbaxy Laboratories Limited composição tópica sob a forma de uma solução e método para tratar acne ou outros distúrbios relacionados à pele
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
MX2012003220A (es) 2009-09-15 2012-08-03 Quadra Logic Tech Inc Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.
ES2661812T3 (es) 2009-10-16 2018-04-04 Mochida Pharmaceutical Co., Ltd. Composiciones
KR101851249B1 (ko) 2010-04-19 2018-06-20 노벨리언 테라퓨틱스 인코포레이티드 내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료용 조성물, 제형 및 키트
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
KR102133608B1 (ko) 2012-03-01 2020-07-13 레티나제닉스, 엘엘씨 내인성 레티노이드 결핍증과 관련된 시각 장애에서 시각 기능의 개선을 위한 치료 요법 및 방법
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
WO2019205030A1 (zh) * 2018-04-25 2019-10-31 人福普克药业（武汉）有限公司 盐酸金刚烷胺软胶囊及其制备方法
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3124510A (en) * 1964-03-10 Stable dry powdered fat-soluble
ZA713539B (en) * 1970-06-23 1972-02-23 Hoffmann La Roche Pharmaceutical compositions
GB1590864A (en) * 1978-05-16 1981-06-10 Lilly Industries Ltd Thixotropic filling medium for hard gelatin capsules
US4322438A (en) * 1979-08-06 1982-03-30 United States Of America Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne
CH658387A5 (de) * 1984-04-02 1986-11-14 Hoffmann La Roche Pharmazeutische praeparate.

Also Published As

Publication number Publication date
EP0184942A3 (en) 1987-08-05
EP0184942B1 (en) 1990-08-08
AU583568B2 (en) 1989-05-04
JPS61145114A (ja) 1986-07-02
DE3579128D1 (de) 1990-09-13
ATE55247T1 (de) 1990-08-15
DK581185D0 (da) 1985-12-13
AU5122685A (en) 1986-07-17
CA1282326C (en) 1991-04-02
EP0184942A2 (en) 1986-06-18
DK581185A (da) 1986-06-15
PH21591A (en) 1987-12-11

Similar Documents

Publication Publication Date Title
AU583568B2 (en) Improved pharmaceutical composition containing 13-cis vitamin A acid as the active ingredient
DE3572767D1 (en) Pharmaceutical composition
AU5566286A (en) Hydralonic acid compositions
IL95691A0 (en) Thienylcarboxylates of amino alcohols,their preparation and pharmaceutical compositions containing them
AU614726B2 (en) Substituted alpha-amino acids, their preparation and pharmaceutical compositions containing them
AU532114B2 (en) Salts of n-substituted-2-pyrrolidone-4-carboxylic acids
AU5354286A (en) Pyrethroidal composition comprising more than one active ingredients
EP0215596A3 (en) Composition for injection of active type vitamins d3
GR3006426T3 (enExample)
IL74734A0 (en) Substituted alpha-amino acids,their preparation and pharmaceutical compositions containing them
GB8500253D0 (en) Slaicyclic acid esters as perfume
AU574206B2 (en) Pharmaceutical composition comprising a pyrimido- pyrimidine and an o-acetylsalicylic acid
AU5425886A (en) Anticalculus oral composition containing phosphonoformic acid
HUT41960A (en) Insecticide compositions containing 2,6,7-trioxa-bicyclo/2,2,2/octane derivatives as active agents and process for producing the active agents and intermediates
AU561025B2 (en) 2,2-dimethyl-5-phenoxypentanoic acid benzamides
IE882836L (en) Antiviral preparations
AU569176B2 (en) Preparation of 2,4-dichloro-5-fluoro-benzoic acid
AU4854685A (en) Preparation of 5,6,7,8-tetrahydrofolic acid
EP0226842A3 (en) Substituted 1,4-naphthalenediones, processes for their preparation and pharmaceutical compositions containing them
NZ218614A (en) 16,17-butylidenedioxy-6,9-difluoro-11-hydroxy-3, 20-dioxopregna-1,4-diene-21-oic acid esters and pharmaceutical compositions
IL76177A0 (en) Substituted 2-phenyl-1,3-dioxolanes,their manufacture and pharmaceutical compositions containing them
DE3660806D1 (en) Novel compound, its production and insecticidal and acaricidal composition containing it as an active ingredient
IL68195A (en) Dermatological preparations containing as active ingredients 1alpha-hydroxycholecalciferol or 1alpha,25-dihydroxy-cholecalciferol
IE853162L (en) Composition containing 13-cis vitamin a acid
AU637530B2 (en) Novel galenical formulations